Compare · SERM
Raloxifene vs Tamoxifen
Both are serm compounds. Here's how they line up on the evidence — graded the same way.
| Raloxifene | Tamoxifen | |
|---|---|---|
| Evidence | Strong human | Strong human |
| Class | SERM | SERM |
| Summary | Raloxifene is a selective estrogen receptor modulator (SERM) — an FDA-approved postmenopausal osteoporosis and breast-cancer-risk-reduction drug, not a peptide. Its defining serious risks are blood clots and fatal stroke; it is banned in sport at all times (WADA S4.2). | Tamoxifen is a selective estrogen receptor modulator (SERM) — an FDA-approved breast-cancer drug with one of the strongest evidence bases in oncology, not a peptide. Anabolic-steroid users take it off-label to blunt gynecomastia and attempt testosterone 'restart,' an unstudied practice that is banned in sport (WADA S4.2) and not without real risk. |
| Full profile → | Full profile → |
Raloxifene
Raloxifene, sold as Evista, is an oral, once-daily selective estrogen receptor modulator (SERM) — a legitimate, well-characterized prescription drug. It is important to be precise about what it is: raloxifene is not a peptide, not an aromatase inhibitor (which is a different anti-estrogen…
Tamoxifen
Tamoxifen, sold as Nolvadex, is a selective estrogen receptor modulator (SERM) and one of the most thoroughly studied drugs in all of oncology. It is important to be precise about what it is: tamoxifen is not a peptide, not an aromatase inhibitor (those, like anastrozole and exemestane, block…